Affinage

Showing UBE2V1 — UEV1A is a alias.

UBE2V1

Ubiquitin-conjugating enzyme E2 variant 1 · UniProt Q13404

Length
147 aa
Mass
16.5 kDa
Annotated
2026-06-10
31 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

UBE2V1 (Uev1A/CROC-1) is a catalytically inactive ubiquitin-conjugating enzyme variant that lacks the canonical E2 active-site cysteine and cannot itself transfer ubiquitin, instead functioning as a specificity-determining cofactor that obligately heterodimerizes with the E2 Ubc13 to direct synthesis of Lys63-linked polyubiquitin chains (PMID:9418904, PMID:16129784). Within this complex, Ubc13 catalyzes thioester-linked ubiquitin transfer while UBE2V1 binds and positions the acceptor ubiquitin so that its Lys63 lies proximal to the active site, enabling processive chain elongation distinct from the UBE2V1-independent initial substrate-modification step (PMID:17709375, PMID:16893187). A unique N-terminal extension absent from the paralog Mms2 stimulates chain assembly, weakens the Uev-Ubc13 affinity, and specifically routes the complex toward NF-κB activation rather than DNA-damage tolerance, explaining why Ubc13-Uev1A drives inflammatory signaling while Ubc13-Mms2 serves DNA repair (PMID:32659264, PMID:16129784). Functionally, Ubc13-Uev1A operates downstream of TNF through TRAF2 polyubiquitination to activate JNK/SAPK signaling (PMID:12591926) and is sufficient on its own to elevate NF-κB activity, upregulate Bcl-2, and confer apoptotic resistance (PMID:17041755); this activity is pharmacologically tractable, as the inhibitor NSC697923 blocks Ubc13~ubiquitin thioester formation and suppresses NF-κB-dependent lymphoma survival (PMID:22791293). Through NF-κB- and AKT-driven programs, UBE2V1 promotes cancer cell invasion, metastasis, and chemoresistance via effectors including MMP1, CXCL1, and AKT-FOXO1-BIM signaling (PMID:25022892, PMID:29662619, PMID:31827405). UBE2V1 also acts in Ubc13-independent or alternative contexts: it positively regulates K63-linked ubiquitinated protein aggregate formation, with cardiomyocyte- and oocyte-level consequences for proteostasis (PMID:32081062, PMID:40394227), partners with Smurf1 to degrade Smad1 (PMID:28771228), and with UBE2S can drive non-K63 (K11/K48) ubiquitination affecting VHL and Cyclin A turnover (PMID:41446875, PMID:41879050).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1998 High

    Established that UEV proteins are catalytically dead E2 variants, reframing UBE2V1 from a presumptive enzyme to a regulatory cofactor with cell-cycle consequences.

    Evidence In vitro ubiquitin conjugation/transfer assays and gain-of-function overexpression in HT-29-M6 cells

    PMID:9418904

    Open questions at the time
    • Did not identify the partner E2 that supplies catalytic activity
    • Mechanism linking UEV expression to Cdk1 inhibition unresolved
  2. 1998 Medium

    Cross-species complementation showed UEV function is conserved, implicating it in DNA-damage tolerance and transcriptional activation before its biochemical partner was known.

    Evidence Yeast mms2/YGL087c deletion complementation, DNA damage sensitivity, and c-fos-CAT reporter assays

    PMID:9580084 PMID:9705497

    Open questions at the time
    • Did not distinguish direct versus indirect contributions to transcription
    • Partner requirements not defined
  3. 2003 High

    Placed Ubc13/Uev1A in the TNF→TRAF2→SAPK/JNK axis, linking K63 chain assembly to a defined signaling cascade.

    Evidence Dominant-negative Ubc13, siRNA, reciprocal co-IP of TRAF2/GCKR, and kinase activity assays

    PMID:12591926

    Open questions at the time
    • Did not resolve which ubiquitination events are direct substrates versus chain extension
  4. 2005 High

    Demonstrated that the Uev partner determines Ubc13 pathway selectivity—Uev1A for NF-κB, Mms2 for DNA repair—and tunes chain length.

    Evidence In vitro chain-length assays, RNAi knockdown, NF-κB reporters, and DNA damage survival assays

    PMID:16129784

    Open questions at the time
    • Structural basis for the partner-specific divergence not yet defined
  5. 2006 High

    Defined the structural mechanism by which Uev1A positions the acceptor ubiquitin for K63 linkage.

    Evidence NMR structure of hUev1a, interaction mapping, and restrained MD modeling of the Ub-Uev1a-Ubc13-Ub tetramer

    PMID:16893187

    Open questions at the time
    • Model is computational for the tetramer; no high-resolution co-crystal of the full assembly
  6. 2007 High

    Dissected chain assembly into a Uev1A-independent substrate-priming step and a Uev1A-dependent elongation step.

    Evidence In vitro reconstitution with UBC13-UEV1A and TRAF6

    PMID:17709375

    Open questions at the time
    • In vitro system; in-cell partitioning of priming versus elongation not measured
  7. 2006 Medium

    Showed UBE2V1 overexpression alone is sufficient to drive NF-κB activity and an anti-apoptotic, pro-survival phenotype.

    Evidence Stable overexpression, NF-κB luciferase reporter, Bcl-2 Western blot, and RNAi rescue in human cells

    PMID:17041755

    Open questions at the time
    • Direct E3/substrate steps connecting UBE2V1 to Bcl-2 induction not mapped
  8. 2012 High

    Validated the Ubc13-Uev1A complex as a druggable node by blocking thioester formation to suppress NF-κB-dependent tumor survival.

    Evidence Small-molecule inhibitor (NSC697923) thioester assay, NF-κB reporter, and DLBCL viability with genetic knockdown

    PMID:22791293

    Open questions at the time
    • Inhibitor selectivity against other thioester-forming E2s not fully characterized
  9. 2010 Medium

    Extended UBE2V1 function to membrane-receptor trafficking via an ortholog, linking K63 ubiquitination to endosomal sorting of glutamate receptors.

    Evidence C. elegans forward genetic screen, GLR-1::GFP imaging, ubc-13 epistasis, and UEV-1/UBC-13 co-IP

    PMID:21179194

    Open questions at the time
    • E3 ligase and direct substrate in the trafficking step not identified
    • Conservation of this role in mammals untested in this corpus
  10. 2017 Medium

    Revealed Ubc13-independent and feedback-regulatory functions: degradation of Smad1 with Smurf1 and K63-modification of RHBDF2 to attenuate TNF signaling.

    Evidence Co-IP, K63-ubiquitination and TACE maturation assays, with Smad1/RHBDF2 readouts

    PMID:28771228 PMID:29069608

    Open questions at the time
    • Single-lab co-IP evidence for each partnership
    • Switch between Ubc13-dependent and -independent modes not mechanistically defined
  11. 2018 Medium

    Connected UBE2V1 to epigenetic and metastatic programs through Sirt1 degradation and NF-κB-driven chemokine/protease effectors.

    Evidence Mass spectrometry, ubiquitination assays, and xenograft models in colorectal and breast cancer (Sirt1, CXCL1, MMP1)

    PMID:25022892 PMID:29662619 PMID:30016968

    Open questions at the time
    • Direct versus indirect contribution to each effector not separated
    • Effects observed largely in overexpression/knockdown settings
  12. 2019 Medium

    Implicated UBE2V1 in AKT-axis survival and chemoresistance beyond NF-κB, including a CT45A-dependent migration program.

    Evidence Bidirectional genetic manipulation with AKT-FOXO1-BIM and CT45A readouts in breast cancer cells

    PMID:31827405 PMID:34503444

    Open questions at the time
    • Biochemical link between UBE2V1 ubiquitination activity and AKT activation undefined
  13. 2020 High

    Defined the N-terminal extension as the molecular determinant that confers Uev1A-specific NF-κB activity, separating it from Mms2.

    Evidence In vitro polyubiquitination, thermodynamic binding measurements, and chimeric/truncation domain swaps with NF-κB reporters

    PMID:32659264

    Open questions at the time
    • How the N-terminus mechanically enhances chain assembly at atomic resolution unresolved
  14. 2020 High

    Established UBE2V1 as a positive regulator of K63-linked protein aggregate formation with in vivo proteostasis and cardiac consequences.

    Evidence Cardiomyocyte overexpression/knockdown, UPS reporter, and AAV9-CRISPR cardiomyocyte-specific knockout in mice

    PMID:32081062

    Open questions at the time
    • E3 partners and substrates driving aggregate formation not identified
  15. 2020 Medium

    Confirmed the conserved heterodimerization interface and dual repair/neurological roles using the Drosophila ortholog.

    Evidence Co-IP with F15E/F15Y mutagenesis, yeast complementation, DNA-damage sensitivity, and fly behavioral analysis

    PMID:32702441

    Open questions at the time
    • Relevance of the neurological phenotype to mammalian UBE2V1 untested in this corpus
  16. 2025 Medium

    Uncovered non-canonical, non-K63 proteolytic functions of UBE2V1 acting with UBE2S to control VHL/HIF-1α and APC/C-dependent Cyclin A turnover.

    Evidence Co-IP, K11/K48-specific and Cyclin A degradation assays, HIF-1α reporter, Drosophila APC/C screen, and xenografts

    PMID:41446875 PMID:41879050

    Open questions at the time
    • How UBE2V1 switches between K63 and K11/K48 chain types not mechanistically resolved
    • Single studies per claim
  17. 2025 Medium

    Linked UBE2V1-driven aggregate regulation to reproductive aging via oocyte aggresome dynamics.

    Evidence Advanced maternal age mouse model, oocyte overexpression/knockdown, and aggresome/maturation readouts

    PMID:40394227

    Open questions at the time
    • Directionality of UBE2V1's effect on aggresomes appears context-dependent and is not reconciled with cardiomyocyte data
    • Substrates in oocytes unidentified

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular switch governing how UBE2V1 selects between Ubc13-dependent K63 chain elongation, Ubc13-independent E3 partnerships, and UBE2S-dependent K11/K48 proteolytic ubiquitination remains undefined.
  • No structural or biochemical model unifying the distinct chain-type and partner choices
  • Substrate specificity determinants across contexts unmapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-168256 Immune System 3 R-HSA-73894 DNA Repair 2
Partners
RHBDF2SMURF1TRAF2TRAF6UBE2NUBE2SVHL
Complex memberships
Ubc13-Uev1A E2 complex

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 Uev1A (UBE2V1) and Mms2 differentially modulate the length of Ubc13-mediated Lys63-linked polyubiquitin chains; Ubc13-Uev1A is specifically required for NF-κB activation but not DNA damage repair, whereas Ubc13-Mms2 is required for DNA damage repair but not NF-κB activation, demonstrating that different Uev partners direct Ubc13 to distinct cellular processes through physical interaction. In vitro polyubiquitination assays, functional complementation, RNA interference knockdown, NF-κB reporter assays, DNA damage survival assays The Journal of cell biology High 16129784
2003 TNF-induced activation of GCKR and the SAPK/JNK pathway requires the E2 complex Ubc13/Uev1A and the E3 TRAF2; TNF signaling leads to TRAF2 polyubiquitination and oligomerization and to GCKR ubiquitination and activation, all sensitive to disruption of Ubc13 function. Dominant-negative interference with Ubc13, siRNA knockdown of Ubc13, immunoprecipitation, kinase activity assays, co-immunoprecipitation of TRAF2 and GCKR The Journal of biological chemistry High 12591926
2007 In an in vitro reconstituted system, UEV1A presents Lys63 of ubiquitin to suppress direct substrate modification while enabling Lys63-linked ubiquitin chain synthesis; protein modification with K63-linked chains occurs through a UEV1A-independent substrate modification step and a UEV1A-dependent chain-elongation mechanism. In vitro ubiquitination reconstitution assay with UBC13-UEV1A and TRAF6 The Journal of biological chemistry High 17709375
2006 NMR structure of hUev1a determined; hUev1a interacts with ubiquitin and hUbc13; a structural model of the Ub-hUev1a-hUbc13-Ub tetramer proposes that a hydrogen-bond network involving hUbc13-Asp81 and Ub-Glu64 positions Ub-Lys63 proximal to the active site for K63-linked chain synthesis. NMR spectroscopy, structural modeling, restrained molecular dynamics simulations Biochemistry High 16893187
1998 UEV-1 (UBE2V1/CROC-1) proteins lack the catalytic cysteine of E2 enzymes and are catalytically inactive in vitro (cannot conjugate or transfer ubiquitin to substrates); constitutive expression of UEV in HT-29-M6 cells inhibited differentiation upon confluence, caused G2-M accumulation, and inhibited the mitotic kinase Cdk1. In vitro ubiquitin conjugation/transfer assay, sequence analysis, cell cycle analysis by flow cytometry, constitutive overexpression in HT-29-M6 cells Molecular and cellular biology High 9418904
2012 The small-molecule NSC697923 inhibits the Ubc13-Uev1A E2 complex by blocking formation of the Ubc13-ubiquitin thioester conjugate, thereby suppressing constitutive NF-κB activity and inhibiting proliferation and survival of DLBCL cells; Ubc13 knockdown similarly inhibited DLBCL cell survival. Small-molecule inhibitor screen, thioester conjugate formation assay, NF-κB reporter assay, siRNA knockdown, cell proliferation/survival assays Blood High 22791293
2018 Ube2v1 promotes Ubc13-mediated ubiquitination and proteasomal degradation of Sirt1, leading to inhibition of histone H4 lysine 16 acetylation and epigenetic suppression of autophagy gene expression, which promotes EMT and metastasis in colorectal cancer. Quantitative mass spectrometry, immunoprecipitation, ubiquitination assay, Western blotting, immunofluorescence, in vivo xenograft model Journal of hematology & oncology Medium 30016968
2014 Uev1A-Ubc13 complex promotes breast cancer cell invasion and metastasis through NF-κB activation and upregulation of MMP1; this process requires functional Ubc13 (physical interaction with Uev1A is necessary), and depletion of UEV1 reduces MMP1 expression and prevents tumor formation/metastasis in xenograft mice. Overexpression and siRNA knockdown in MDA-MB-231 cells, NF-κB reporter assay, invasion/migration assays, xenograft mouse model, MMP1 rescue experiment Breast cancer research : BCR Medium 25022892
2017 Uev1A-Ubc13 complex interacts with RHBDF2 and, upon TNFα stimulation cooperates with the E3 CHIP to promote K63-linked ubiquitination of RHBDF2, enhancing TACE maturation and subsequent shedding of the TNFα receptor to attenuate NF-κB signaling. Co-immunoprecipitation, K63-linked ubiquitination assay, TACE maturation assay, UEV1A overexpression and inhibition experiments Cellular signalling Medium 29069608
2017 Uev1A promotes osteosarcoma differentiation by collaborating with the E3 ligase Smurf1 to promote ubiquitination and degradation of Smad1 (a BMP signaling effector), and this process occurs in a Ubc13-independent manner. Co-immunoprecipitation, ubiquitination assay, Western blotting, UEV1A overexpression and knockdown, Smad1 as downstream effector readout Cell death & disease Medium 28771228
2020 Ube2v1 positively regulates K63-linked ubiquitination to promote protein aggregate formation in cardiomyocytes; Ube2v1 knockdown improves ubiquitin proteasome system performance and promotes degradation of insoluble ubiquitinated proteins without altering autophagic flux; cardiomyocyte-specific Ube2v1 knockout alleviates CryABR120G-induced protein aggregation, improves cardiac function, and prolongs lifespan in vivo. Adenoviral overexpression/knockdown in neonatal rat ventricular cardiomyocytes, UPS reporter assay, AAV9-CRISPR cardiomyocyte-specific knockout in mice, echocardiography, autophagic flux assay Circulation research High 32081062
2020 The N-terminal extension of Uev1A (absent in Mms2) stimulates polyubiquitin chain assembly, weakens the Uev-Ubc13 interaction affinity, and is specifically required for NF-κB activation; a chimeric protein with the Uev1A N-terminus fused to Mms2 functionally resembles Uev1A, whereas truncated Uev1A lacking the N-terminal extension behaves like Mms2. In vitro polyubiquitination assay, thermodynamic binding measurements (ITC or equivalent), chimeric and truncation mutant functional assays, NF-κB reporter assay Cellular signalling High 32659264
2006 Constitutive high-level expression of UEV1A alone in human cells is sufficient to increase NF-κB activity, upregulate the anti-apoptotic protein Bcl-2, confer prolonged cell survival under serum deprivation, and protect against apoptosis from diverse stressing agents; all effects are reversible upon RNAi-mediated suppression of UEV1. Stable overexpression of UEV1A, NF-κB luciferase reporter assay, Western blotting, RNAi knockdown, cell survival/apoptosis assays Apoptosis : an international journal on programmed cell death Medium 17041755
2018 Uev1A-Ubc13 promotes colorectal cancer metastasis through NF-κB activation and upregulation of CXCL1; UEV1A overexpression depends on its physical interaction with Ubc13 to promote invasion, and depletion of UEV1 reduces CXCL1 expression and prevents tumor growth in a xenograft model. Overexpression and siRNA knockdown in HCT116 cells, NF-κB reporter, invasion assay, xenograft mouse model, IHC of human samples Oncotarget Medium 29662619
2019 UEV1A promotes breast cancer cell survival under serum starvation and chemoresistance through activation of the AKT signaling pathway that in turn inhibits FOXO1 and BIM expression; depletion of UEV1 inhibits AKT signaling and promotes FOXO1/BIM expression, reducing cell survival and enhancing chemosensitivity. Overexpression and siRNA knockdown of UEV1A in MDA-MB-231 and MCF7 cells, Western blotting for AKT/FOXO1/BIM, cell viability and chemosensitivity assays Cancer cell international Medium 31827405
2010 C. elegans UEV-1 (ortholog of UBE2V1) regulates trafficking of the AMPA-type glutamate receptor GLR-1; loss of uev-1 causes GLR-1 accumulation in RAB-10-containing endosomes in neuron cell bodies and along neurites, independent of clathrin-mediated endocytosis; ubc-13 mutants phenocopy uev-1 mutants, and UEV-1 can physically interact with C. elegans UBC-13. Forward genetic screen in C. elegans, fluorescence imaging of GLR-1::GFP, behavioral reversal assay, genetic epistasis with ubc-13, co-immunoprecipitation of UEV-1 and UBC-13, K63-ubiquitin immunostaining PloS one Medium 21179194
2021 UEV1A overexpression induces CT45A family gene expression in breast cancer cells and promotes cell migration and EMT signaling through the AKT pathway (independently of NF-κB); depletion of CT45A abolishes these effects, identifying CT45A as a critical downstream effector of Uev1A in AKT-dependent migration. UEV1A and CT45A overexpression/knockdown in breast cancer cells, gene expression profiling, cell migration assay, Western blotting for AKT and NF-κB pathway components BMC cancer Medium 34503444
2020 Drosophila Uev1a forms a stable heterodimer with Bendless (Drosophila Ubc13 ortholog); Uev1a-F15E mutation abolishes this interaction, and Uev1a-F15Y severely reduces it; dUev1a functionally rescues yeast mms2 null mutants in a Bendless-dependent manner, and heterozygous dUev1a mutant flies show increased sensitivity to DNA-damaging agents and reduced mobility consistent with neurological defects. Co-immunoprecipitation, site-directed mutagenesis (F15E, F15Y), yeast functional complementation, DNA damage sensitivity assay, Drosophila mutant behavioral analysis Cellular signalling Medium 32702441
2025 UBE2V1 competes with HIF-1α for binding to the β-domain of VHL protein and, in complex with UBE2S, catalyzes K11/K48-linked ubiquitination of VHL at K196, leading to VHL proteasomal degradation, reduced HIF-1α ubiquitination, and sustained HIF-1α stabilization, creating a positive feedback loop in hepatocellular carcinoma. Co-immunoprecipitation, ubiquitination assay (K11/K48-specific), UBE2V1 overexpression/knockdown, HIF-1α reporter assay, VHL degradation assay, in vivo xenograft Research (Washington, D.C.) Medium 41446875
1998 Human UEV-1A cDNA fully complements the UV and MMS sensitivity of a yeast YGL087c deletion mutant, demonstrating functional conservation of UEV proteins in DNA damage tolerance across species. Yeast deletion mutant complementation assay, DNA damage sensitivity assay (UV and MMS) FEBS letters Medium 9580084
1998 Human UEV (CROC-1/hMMS2) genes complement yeast mms2 defects in DNA damage sensitivity and spontaneous mutagenesis, and both MMS2 and hMMS2 transactivate a c-fos-CAT reporter gene in mammalian cells, demonstrating functional conservation across species in both DNA repair and transcriptional activation. Yeast mms2 mutant complementation assay, transient co-transfection with c-fos-CAT reporter in Rat-1 cells Nucleic acids research Medium 9705497
2025 UBE2V1 positively regulates ubiquitinated protein aggregate formation in mouse oocytes; UBE2V1 expression increases with maternal aging and correlates with aggresome formation; restoring UBE2V1 expression in aged oocytes/embryos alleviates aggresome formation and partly ameliorates age-related defects in oocyte maturation and embryo development. Mouse model of advanced maternal age, UBE2V1 overexpression/knockdown in oocytes, immunofluorescence for ubiquitinated aggregates/aggresomes, oocyte maturation and embryo development assessment Communications biology Medium 40394227
2025 Uev1A collaborates with the E3 APC/C complex to mediate proteasomal degradation of Cyclin A in Drosophila, representing a non-canonical (proteolytic) function; this protects polyploid nurse cells from oncogenic Ras-induced aberrant division stress; human UBE2V1 and UBE2V2 similarly counteract oncogenic Ras-driven tumorigenesis in vivo. Genome-wide genetic screen in Drosophila, genetic epistasis, Cyclin A degradation assay, xenograft tumor model in nude mice with human UBE2V1/UBE2V2 overexpression eLife Medium 41879050

Source papers

Stage 0 corpus · 31 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 Distinct regulation of Ubc13 functions by the two ubiquitin-conjugating enzyme variants Mms2 and Uev1A. The Journal of cell biology 151 16129784
2003 Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). The Journal of biological chemistry 149 12591926
2012 Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 130 22791293
1998 Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Molecular and cellular biology 117 9418904
1998 The products of the yeast MMS2 and two human homologs (hMMS2 and CROC-1) define a structurally and functionally conserved Ubc-like protein family. Nucleic acids research 90 9705497
2018 Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy. Journal of hematology & oncology 80 30016968
2008 Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorganic & medicinal chemistry letters 63 19006668
2007 Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme. The Journal of biological chemistry 43 17709375
2020 Ube2v1 Positively Regulates Protein Aggregation by Modulating Ubiquitin Proteasome System Performance Partially Through K63 Ubiquitination. Circulation research 40 32081062
2014 Ubiquitin-conjugating enzyme complex Uev1A-Ubc13 promotes breast cancer metastasis through nuclear factor-кB mediated matrix metalloproteinase-1 gene regulation. Breast cancer research : BCR 40 25022892
1997 CROC-1 encodes a protein which mediates transcriptional activation of the human FOS promoter. Gene 39 9305758
2006 Uev1A, a ubiquitin conjugating enzyme variant, inhibits stress-induced apoptosis through NF-kappaB activation. Apoptosis : an international journal on programmed cell death 33 17041755
1998 Up-regulation of CIR1/CROC1 expression upon cell immortalization and in tumor-derived human cell lines. Oncogene 32 9771976
2016 Simulated Microgravity Promotes Cell Apoptosis Through Suppressing Uev1A/TICAM/TRAF/NF-κB-Regulated Anti-Apoptosis and p53/PCNA- and ATM/ATR-Chk1/2-Controlled DNA-Damage Response Pathways. Journal of cellular biochemistry 31 26887372
2010 UEV-1 is an ubiquitin-conjugating enzyme variant that regulates glutamate receptor trafficking in C. elegans neurons. PloS one 24 21179194
2018 Uev1A-Ubc13 promotes colorectal cancer metastasis through regulating CXCL1 expression via NF-кB activation. Oncotarget 23 29662619
2017 Uev1A facilitates osteosarcoma differentiation by promoting Smurf1-mediated Smad1 ubiquitination and degradation. Cell death & disease 23 28771228
2017 Uev1A-Ubc13 catalyzes K63-linked ubiquitination of RHBDF2 to promote TACE maturation. Cellular signalling 20 29069608
2002 A homologue of CROC-1 in a ciliated protist (Sterkiella histriomuscorum) testifies to the ancient origin of the ubiquitin-conjugating enzyme variant family. Molecular biology and evolution 18 11752188
1998 Role of UEV-1A, a homologue of the tumor suppressor protein TSG101, in protection from DNA damage. FEBS letters 16 9580084
2019 Uev1A promotes breast cancer cell survival and chemoresistance through the AKT-FOXO1-BIM pathway. Cancer cell international 15 31827405
2006 Structure and interactions of the ubiquitin-conjugating enzyme variant human Uev1a: implications for enzymatic synthesis of polyubiquitin chains. Biochemistry 14 16893187
2023 Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis and sequestering USP10. International journal of medical sciences 12 37786443
2021 Uev1A promotes breast cancer cell migration by up-regulating CT45A expression via the AKT pathway. BMC cancer 7 34503444
2020 Drosophila Uev1a is dually required for Ben-dependent DNA-damage response and fly mobility. Cellular signalling 6 32702441
2021 Expression and clinical significance of UBE2V1 in cervical cancer. Biochemistry and biophysics reports 5 34466666
2020 Uev1A amino terminus stimulates poly-ubiquitin chain assembly and is required for NF-κB activation. Cellular signalling 3 32659264
2025 UBE2V1 Promotes Hepatocellular Carcinoma Progression by Forming a Positive Feedback Loop with HIF-1α. Research (Washington, D.C.) 2 41446875
2025 UBE2V1 governs aging induced protein aggregation and developmental defects in oocytes and embryos. Communications biology 1 40394227
2026 Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cells. eLife 0 41879050
2026 CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation. Scientific reports 0 42215525

Missed literature

Know a paper Affinage missed for UBE2V1? Flag it for the maintainers and the community.

No submissions yet.